NCT03208660 is a clinical trial of Fycompa in Epilepsy, sponsored by Eisai Inc..

Who is sponsoring NCT03208660?

NCT03208660 is sponsored by Eisai Inc..

What drugs are being tested in NCT03208660?

Interventions in NCT03208660: Fycompa.

Is NCT03208660 still recruiting?

NCT03208660 is currently completed. Last updated 11 April 2019.

Last reviewed 2019-04-11 · How we verify

NCT03208660

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

Completed Last updated 11 April 2019

What this trial tests

trial testing Fycompa in Epilepsy in 2,000 participants. Completed in 15 March 2019.

Timeline

7 April 2017

Primary endpoint
15 March 2019

15 March 2019

Quick facts

Lead sponsor	Eisai Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,000
Start date	7 April 2017
Primary completion	15 March 2019
Estimated completion	15 March 2019
Sites	44 locations across United States

Drugs / interventions tested

Fycompa (PERAMPANEL) — full drug profile →

Conditions studied

Epilepsy — all drugs for Epilepsy →

Sponsor

Eisai Inc. — full company profile →

Who can join

Eligibility, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is conducted to assess the retention rate of Fycompa when given in routine clinical care.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

PROVE: Retrospective, non-interventional, Phase IV study of perampanel in real-world clinical care of patients with epilepsy.
Wechsler RT, Wheless J, Zafar M, Huesmann GR, et al · · 2022 · cited 24× · PMID 34942053 · DOI 10.1002/epi4.12575
Perampanel in real-world clinical care of adolescent and adult patients with epilepsy: Results from the retrospective Phase IV PROVE Study.
Segal E, Wheless J, Moretz K, Penovich P, et al · · 2022 · cited 12× · PMID 35453064 · DOI 10.1016/j.seizure.2022.02.011
Perampanel in real-world clinical care of patients with epilepsy: Interim analysis of a phase IV study.
Wheless J, Wechsler RT, Lancman M, Aboumatar S, et al · · 2021 · cited 12× · PMID 33681651 · DOI 10.1002/epi4.12445
Real-world use of adjunctive perampanel for focal-onset seizures in Italy: A mirroring clinical practice study of perampanel in adults and adolescents (AMPA).
D'Aniello A, Giallonardo AT, Tinuper P, Mecarelli O, et al · · 2025 · cited 3× · PMID 40468531 · DOI 10.1002/epi4.70068
Phase IV PROVE study: Perampanel in real-world clinical care of pediatric patients with epilepsy.
Moretz K, Wheless J, Santos C, Segal E, et al · · 2024 · cited 2× · PMID 38569352 · DOI 10.1016/j.ejpn.2024.02.008

Verify or expand the search:

Other trials of Fycompa

Trials testing the same drug.

NCT05201703 — Fycompa in Catamenial Epilepsy · Phase 4 · terminated
NCT03377309 — Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients · Phase 2 · terminated
NCT03059381 — Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Pa · completed
NCT03059329 — Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients · completed

Other recruiting trials for Epilepsy

Currently open trials in the same condition.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting

Other Eisai Inc. trials

Trials by the same sponsor.

NCT07493265 — A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy · Phase 2 · not yet recruiting
NCT07308236 — A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants · Phase 1 · recruiting
NCT06854042 — A Study of Oral E1018 in Healthy Adult Participants · Phase 1 · recruiting
NCT06744673 — A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control P · active not recruiting
NCT06602258 — A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03208660 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eisai Inc.
Last refreshed: 11 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03208660.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing